25.04.2016 • NewsCEODede WillamsJoseph C. Papa

Valeant on Verge of Hiring Perrigo’s CEO?

In its search for a new CEO to replace William J. Pearson, who has resigned amid several controversies, Canada-domiciled  embattled drugmaker Valeant is said to be finalizing a contract with Joseph C. Papa, chairman and CEO of Ireland-domiciled pharmaceutical producer Perrigo. Neither of the companies – both managed from the US – has been willing to comment on the speculation launched by The Wall Street Journal, which said the appointment could be announced as early as this week.

Valeant is under heavy scrutiny in the US Senate for price gouging. It also is being subjected to a US federal government audit of its accounting and pricing practices, as well more than one Securities and Exchange Commission (SEC) investigation.

Among other things, the SEC is looking into issues at Salix Pharmaceuticals, which was acquired by Valeant for $11 billion in 2015.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.